中国临床药学杂志

参考文献

[1] Ham m J.Phase and studies of toremifene.Oncology,1997,11:19

[2 ] Gams R.Phase trials of toremifene vs tamoxifene.Oncolo-gy,1997,11:2 3

[3 ] Warri AM,Huovinen RL ,Laine AM,et al. Apoptosis intorem ifene-induced growth inhibition of human breast cancercells in vivo and in vitro. JNatl Cancer Insti,1993 ,85 :14 12

[4] Coradini D,Biffi A,Cappelletti V,etal.Effects of toremifeneand its main metabolites on growth of breast cancer cell lines.Anticancer Res,1991,11:2 191

[5 ] Anttila M,Valavaara R,Kivinen S,etal. Pharm acokinetics oftoremifene. JSteroid Biochem ,1990 ,3 6:2 49

[6] Asaishi K,Tominaga T,Abe O,et al.Efficacy and safety ofhigh dose NK 62 2 (toremifene citrate) in tam oxifene failed pa-tients with breast cancer.Gan to Kagaku Ryoho,1993 ,2 0 :91

[7] Vogel CL ,Shemano I,Schoenfelder J,etal. Multicenter phase efficacy trial of toremifene in tam oxifene refractory patientswith advanced breast cancer. JClin Oncol,1993 ,11:3 4 5

[8] Phrhonen S,Valavaara R,Vuorinen J,et al.High dose tore-mifene in advanced breast cancer resistant to or relapsed duringtam oxifene treatment. Breast Cancer Res Treat,1994,2 9(3 ) :2 2 3

[9]冯奉仪 ,许立功 ,何友谦 ,等 .法乐通治疗乳腺癌临床总结 .癌症杂志 ,1999,18(3 ) :2 1

[10 ] Saarto T,Blomqvist C,Ehnholm C,etal. Antiatherogenic ef-fects of adjuvant antiestrogens:a randomized trial comparingthe effects of tam oxifen and toremifene on plasm a lipid levels inpostmenopausal women with node-positive breast cancer. JClin Oncol,1996,14 (2 ) :42 9

[11] Tominaga T,Abe O,Izuo M,et al. A phase study oftoremifene.Breast Cancer Res Treat,1990 ,16(Suppl) :2 7